Trial Profile
A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Dec 2023
Price :
$35
*
At a glance
- Drugs Tivozanib (Primary) ; Sorafenib
- Indications Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms TIVO-3
- Sponsors AVEO Oncology
- 17 Mar 2023 Results of subgroup analysis assessing the clinical efficacy of tivozanib in patients with advanced metastatic renal cell carcinoma previously treated with axitinib, published in the Oncologist.
- 07 Jun 2022 Results assessing the contribution of event accumulation and data maturation on the stability of KM survival estimates, presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
- 06 Jun 2022 According to an AVEO Oncology media release, data from this trial were presented during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract: 4557; Poster: 48).